Advances in application of sodium-glucose co-transporter 2 inhibitor in elderly type 2 diabetes mellitus patients with concomitant common cardiovascular diseases
Elderly patients with type 2 diabetes mellitus(T2DM)often have multiple coexisting diseases,and the complication of cardiovascular diseases(CVD)is the most common,which is the primary cause of disability and death.Sodium-glucose co-transporter protein 2 inhibitor(SGLT2i)is a novel hypoglycemic agent,which has received widespread attention for its cardio-protective effects,and shows good prospects for the treatment of co-morbidities of T2DM and CVD in the elderly.In this article,we reviewed the progress of SGLT2i in T2DM combined with heart failure,hypertension,atherosclerosis,myocardial infarction and other common CVD.
diabetes mellitus,type 2sodium-glucose co-transporter protein 2 inhibitorgeriatric co-morbiditiescardiovascular diseasesheart failure
NETL
NSTL
万方数据
